开普拓联合5-氟尿嘧啶治疗对5-氟尿嘧啶耐药晚期大肠癌的临床效果  

Clinical effects of camptothecin plus 5-fluorouracil in treating patients with 5-fluorouracil resistant advanced colorectal cancer

作　　者：王建军[1] 刘大晗[2] 

机构地区：[1]河南大学淮河医院肿瘤科,河南省开封市475001 [2]河南大学淮河医院普通外科,河南省开封市475001

出　　处：《世界华人消化杂志》2015年第14期2341-2345,共5页World Chinese Journal of Digestology

摘　　要：目的:分析开普拓联合5-氟尿嘧啶(5-fluorouracil,5-Fu)治疗对5-Fu耐药的晚期大肠癌的疗效.方法:按照化疗方案不同将85例对5-Fu耐药的晚期大肠癌患者分为实验组(开普拓+5-Fu)45例和对照组(开普拓)40例,比较两组患者疗程结束时临床疗效、化疗前后生活质量评分变化情况以及不良反应发生情况.结果:实验组患者部分缓解率(p a r t i a l remission,PR)、总有效率(overall response r a t e,R R)及临床获益率(c l i n i c a l b e n e f i t r a t e,C B R)均显著高于对照组(64.44%v s35.00%、64.44%v s 35.00%、88.89%v s57.50%),差异具有统计学意义(P<0.05);两组患者化疗后躯体功能、角色功能、认知功能、情绪功能、社会功能评分均显著升高,与同组化疗前比较(88.56分±7.24分vs68.33分±9.24分、75.89分±7.03分vs 53.78分±9.67分、80.56分±7.24分vs 59.33分±9.24分、81.89分±7.03分vs 58.78分±9.67分、74.78分±7.86分vs 52.74分±9.46分,78.53分±7.55分vs 68.35分±9.33分、64.88分±7.02分vs 53.75分±9.80分、69.93分±7.55分vs 59.35分±9.33分、69.28分±7.00分vs 58.75分±9.80分、61.94分±7.89分v s 51.73分±9.85分),差异具有统计学意义(P<0.05);实验组患者化疗后躯体功能、角色功能、认知功能、情绪功能、社会功能评分均显著高于对照组(88.56分±7.24分vs78.53分±7.55分、75.89分±7.03分vs 64.88分±7.02分、80.56分±7.24分vs 69.93分±7.55分、81.89分±7.03分vs 69.28分±7.00分、74.78分±7.86分vs 61.94分±7.89分),差异具有统计学意义(P<0.05);两组患者胃肠反应、恶心呕吐、中性粒细胞减少、乙酰胆碱综合征、血小板减少、贫血发生率发生率及严重程度比较(42.22%vs 52.50%、4.44%vs 7.50%、40.00%vs 60.00%、0.00%v s 0.00%、35.56%v s 42.50%、11.11%v s15.00%、26.67%v s 20.00%、0.00%v s0.00%,13.33%vs 12.50%、2.22%vs 5.00%,13.33%vs 17.50%、0.00%vs 0.00%),差异均无统计学意义(P>0.05).结论:开普拓联合5-Fu方案临床疗效显著,可以明AIM：To evaluat e t he clinical effect s of camptothecin plus 5-fluorouracil（5-Fu） in treating patients with 5-Fu resistant advanced colorectal cancer. METHODS： Eighty-five patients with 5-Furesistant advanced colorectal cancer were randomly into a study group（45 cases） and a control group（40 cases）. The clinical effects, the scores of quality of life and side effects were compared for the two groups. RESULTS： The partial remission（PR） rate, overall response rate（RR）, and clinical benefit rate（CBR） for the study group were significantly higher than those for the control group（64.44% vs 35.00%, 64.44% vs 35.00%, 88.89% vs 57.50%; P〈0.05）. The scores of physical function, role function, cognitive function, emotional function and social function for the two groups of patients after chemotherapy were significantly higher than those before chemotherapy（88.56 ± 7.24 vs 68.33 ± 9.24, 75.89 ± 7.03 vs 53.78 ± 9.67, 80.56 ± 7.24 vs 59.33 ± 9.24, 81.89 ± 7.03 vs 58.78 ± 9.67, 74.78 ± 7.86 vs 52.74 ± 9.46, 78.53 ± 7.55 vs 68.35 ± 9.33, 64.88 ± 7.02 vs 53.75 ± 9.80, 69.93 ± 7.55 vs 59.35 ± 9.33, 69.28 ± 7.00 vs 58.75 ± 9.80, 61.94 ± 7.89 vs 51.73 ± 9.85; P〈0.05）. The scores of physical function, role function, cognitive function, emotional function and social function for the study group after chemotherapy were significantly higher than those for the control group（88.56 ± 7.24 vs 78.53 ± 7.55, 75.89 ± 7.03 vs 64.88 ± 7.02, 80.56 ± 7.24 vs 69.93 ± 7.55, 81.89 ± 7.03 vs 69.28 ± 7.00, 74.78 ± 7.86 vs 61.94 ± 7.89; P〈0.05）. There was no significant difference in the rates of gastrointestinal reaction, nausea and vomiting, neutropenia, acetylcholine syndrome, thrombocytopenia or anemia between the two groups（42.22% vs 52.50%, 4.44% vs 7.50%, 40.00% vs 60.00%, 0.00% vs 0.00%, 35.56% vs42.50%, 11.11% vs 15.00%, 26.67% vs 20.00%,0.00% vs 0.00%, 13.33% vs 12.50%, 2.22% vs 5.00%,13.33% vs 17.50%, 0.00% vs 0.00%; P〈0.05）.CONCLUSION： Camptothecin plus 5-

关 键 词：开普拓 5-氟尿嘧啶 耐药 晚期大肠癌 

分 类 号：R735.34[医药卫生—肿瘤]